Ching-Yu Wang1, Joshua Brown1. 1. Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Abstract
BACKGROUND: The appropriateness of using readmission rate after pancreatic surgery among pancreatic cancer patients as a quality metric to evaluate hospital performance has been widely discussed in the literature. OBJECTIVES: The present study reported readmission rate using Nationwide Readmissions Database (NRD), examined the reasons and risk factors for readmissions, and evaluated the appropriateness of using it as a quality metric. METHOD: We analyzed 3,619 patient discharge records in 2014. The outcome of interest was all-cause 30-day readmission. Reasons for readmission were grouped into clinical associated categories. Hierarchical regression model was used for examining the relationship between risk factors and readmission. RESULTS: The 30-day readmission rate was 20.95%. The most common reason for readmission was surgery-related complication. In descriptive analyses, age, certain comorbidities, number of chronic conditions, mortality risk, severity of illness, living at large metropolitan area, resident of the state where patients received initial care, postoperative complication, length of stay, discharge location, and receiving care at the hospitals in large metropolitan area were predictive of readmission. In multivariable analysis, age, depression, peripheral vascular disorder, mortality risk, and discharge location were independently associated with readmission. The intraclass correlation coefficient was 0.41 for hierarchical regression model. CONCLUSIONS: Readmission after pancreatic surgery remains an important issue. Our study found the majority of variation in readmissions is accounted for by patient factors whereas there was little between hospital variation. This finding does not support the use of readmission rate after pancreatic surgery as a quality metric.
BACKGROUND: The appropriateness of using readmission rate after pancreatic surgery among pancreatic cancer patients as a quality metric to evaluate hospital performance has been widely discussed in the literature. OBJECTIVES: The present study reported readmission rate using Nationwide Readmissions Database (NRD), examined the reasons and risk factors for readmissions, and evaluated the appropriateness of using it as a quality metric. METHOD: We analyzed 3,619 patient discharge records in 2014. The outcome of interest was all-cause 30-day readmission. Reasons for readmission were grouped into clinical associated categories. Hierarchical regression model was used for examining the relationship between risk factors and readmission. RESULTS: The 30-day readmission rate was 20.95%. The most common reason for readmission was surgery-related complication. In descriptive analyses, age, certain comorbidities, number of chronic conditions, mortality risk, severity of illness, living at large metropolitan area, resident of the state where patients received initial care, postoperative complication, length of stay, discharge location, and receiving care at the hospitals in large metropolitan area were predictive of readmission. In multivariable analysis, age, depression, peripheral vascular disorder, mortality risk, and discharge location were independently associated with readmission. The intraclass correlation coefficient was 0.41 for hierarchical regression model. CONCLUSIONS: Readmission after pancreatic surgery remains an important issue. Our study found the majority of variation in readmissions is accounted for by patient factors whereas there was little between hospital variation. This finding does not support the use of readmission rate after pancreatic surgery as a quality metric.
Authors: Jeffrey M Sutton; Gregory C Wilson; Koffi Wima; Richard S Hoehn; R Cutler Quillin; Dennis J Hanseman; Ian M Paquette; Jeffrey J Sussman; Syed A Ahmad; Shimul A Shah; Daniel E Abbott Journal: Ann Surg Oncol Date: 2015-04-04 Impact factor: 5.344
Authors: Zachary J Kastenberg; John M Morton; Brendan C Visser; Jeffrey A Norton; George A Poultsides Journal: HPB (Oxford) Date: 2012-09-24 Impact factor: 3.647
Authors: David Yu Greenblatt; Sharon M Weber; Erin S O'Connor; Noelle K LoConte; Jinn-Ing Liou; Maureen A Smith Journal: Ann Surg Date: 2010-04 Impact factor: 12.969
Authors: C J Yeo; J L Cameron; T A Sohn; K D Lillemoe; H A Pitt; M A Talamini; R H Hruban; S E Ord; P K Sauter; J Coleman; M L Zahurak; L B Grochow; R A Abrams Journal: Ann Surg Date: 1997-09 Impact factor: 12.969
Authors: Irmina Gawlas; Monica Sethi; Megan Winner; Irene Epelboym; James L Lee; Beth A Schrope; John A Chabot; John D Allendorf Journal: Ann Surg Oncol Date: 2012-12-08 Impact factor: 5.344
Authors: Syed A Ahmad; Michael J Edwards; Jeffrey M Sutton; Sanjeet S Grewal; Dennis J Hanseman; Shishir K Maithel; Sameer H Patel; David J Bentram; Sharon M Weber; Clifford S Cho; Emily R Winslow; Charles R Scoggins; Robert C Martin; Hong Jin Kim; Justin J Baker; Nipun B Merchant; Alexander A Parikh; David A Kooby Journal: Ann Surg Date: 2012-09 Impact factor: 12.969
Authors: C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt Journal: Ann Surg Date: 1995-06 Impact factor: 12.969
Authors: Irina Yermilov; David Bentrem; Evan Sekeris; Sushma Jain; Melinda A Maggard; Clifford Y Ko; James S Tomlinson Journal: Ann Surg Oncol Date: 2008-11-11 Impact factor: 5.344
Authors: Xueqiang Deng; Xiaowei Fu; Hong Teng; Lu Fang; Bo Liang; Rengui Zeng; Lian Chen; Yeqing Zou Journal: J Transl Med Date: 2021-08-05 Impact factor: 5.531